Meet Our Team

Collaboration across the human clinical and veterinary fields is rare. For Tharos, pooled expertise offers a distinctive business strength.

The company was born out of a collaboration between biochemist Dr Rosemary Waring and consultant gastroenterologist Professor John Hunter. They have since been joined by renowned scientific colleagues, supported by experienced entrepreneurs.

 

Douglas Dundonald, Chairman

Douglas (Douggie) Dundonald is a founder and director of Anglo Scientific and currently chairs Radio Physics Solutions. He previously served as an executive main board director of Anglo Pacific Group Plc, a quoted (UK and Australia) public company. While an active member of the House of Lords, he held a position on the council of the Parliamentary Information Technology Committee and has been the Honorary Consul of Chile in Scotland for over 25 years. He has been involved in technology companies as an investor and founder for 25 years.

 

Harry Paul, CEO

Harry is an entrepreneur with more than 25 years’ experience in pharma and medical devices. He has held international management roles at Roche and Boston Scientific in the UK, Latin America and India. In 2007 Harry founded H Paul & Partners

in Argentina, developing projects in the Latin American agricultural sector, working in olive oil, grain production, cattle and farmland acquisition and development. In 2015 he founded LatAm HQ Health Ltd, providing regulatory, marketing and distribution solutions for health companies entering Latin America. Harry is a keen linguist, speaking Spanish, Portuguese and French fluently. He also has a passion for horses, having bred and trained polo ponies in Argentina for several years.

 

Professor Teo Forcht Dagi, Director

A Harvard-trained neurosurgeon, Professor Dagi is a Distinguished Scholar and Professor at Queen’s University Belfast and holds faculty appointments at Harvard Medical School. Teo has been managing venture capital investments in the biomedical arena for two decades. His track record includes several quoted companies (NASDAQ) with an aggregate exit value of more than $10bn.

 

Professor John Hunter

A Consultant Physician at Addenbrooke’s Hospital, Cambridge, and Visiting Professor
of Medicine at Cranfield University, Professor Hunter is a recognised authority on diseases of the gut, including Crohn’s disease, colitis and irritable bowel syndrome. He has published books in this field and contributed over 150 research papers to major medical journals. Professor Hunter has been a consultant to international companies including Shell, Unilever, Nutricia, Quest International and Marlow Foods.

 

Dr Rosemary Waring, Director

Dr Waring qualified in Natural Sciences at the University of Cambridge and completed a PhD in Biochemistry at the University of Birmingham, where she was a Reader in Human Toxicology and is involved in research at the School of Biosciences. Currently, her research is focused on the interactions of gut flora with gastrointestinal function using metabolomic analysis. She has written over 230 research papers published in peer-reviewed journals. She is a Fellow of the Royal College of Pathology and has coordinated an EC-funded project on endocrine disruption.

 

Jo Aston, Equine and Commercial

Jo Aston is an international event rider, training horses and riders of all levels.

Jo produces horses for the sports horse market, bringing to the team a thorough knowledge and understanding of the demands placed on the modern equine athlete.

Her extensive experience as a rider and trainer, and her insight into the importance of a horse’s inner health, means she is passionate about new research to optimise performance and achieve results. 20 plus years of working in many areas of the equine sector has given her the respect and understanding of the customer base.

As part of her role as Marketing Advisor, she translates the science into customer friendly language to effectively communicate the Tharos story to the end user.

 

We use cookies to ensure that we give you the best experience on our website. If you continue we'll assume that you are understand this. Learn more
Accept